Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
Recent studies have shown that obese people are more prone to high blood pressure. With the
co-existence of obesity, hypertension and diabetes, patients were more susceptible to
hyperlipidemia, coronary and cerebral atherosclerosis and peripheral vascular disease.
Abdominal obesity has often accompanied by substantial accumulation of visceral fat, which
increased secretion of many inflammatory mediators, cytokines and adipocytokines and played
an important role in cardiovascular and metabolic disease. Some reports had shown that
angiotensin II receptor blockers (ARB) may improve metabolic profiles in patients with
diabetes or metabolic syndrome, in addition to its hypotensive effect. It has been reported
that some ARB, such as telmisartan and candesartan, can prevent weight gain and
high-fat-induced obesity in experimental animals. However, whether telmisartan intervention
on improvement of fat deposition and other related metabolic profiles is better than a CCB
drugs (amlodipine) in those obese hypertensive patients with diabetes, was still unknown.